{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:35:25Z","timestamp":1792164925349,"version":"4.4.0"},"reference-count":45,"publisher":"National Academy of Sciences","issue":"35","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA090625"],"award-info":[{"award-number":["CA090625"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA090625"],"award-info":[{"award-number":["CA090625"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA268703"],"award-info":[{"award-number":["CA268703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA217834"],"award-info":[{"award-number":["CA217834"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI175656"],"award-info":[{"award-number":["AI175656"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA262287"],"award-info":[{"award-number":["CA262287"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK127699"],"award-info":[{"award-number":["DK127699"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA236733"],"award-info":[{"award-number":["CA236733"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA200709"],"award-info":[{"award-number":["CA200709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:p>WD40 Repeat Domain 5 (WDR5) is a highly conserved nuclear protein that recruits MYC oncoprotein transcription factors to chromatin to stimulate ribosomal protein gene expression. WDR5 is tethered to chromatin via an arginine-binding cavity known as the \u201cWIN\u201d site. Multiple pharmacological inhibitors of the WDR5-interaction site of WDR5 (WINi) have been described, including those with picomolar affinity and oral bioavailability in mice. Thus far, however, WINi have only been shown to be effective against a number of rare cancer types retaining wild-type p53. To explore the full potential of WINi for cancer therapy, we systematically profiled WINi across a panel of cancer cells, alone and in combination with other agents. We report that WINi are unexpectedly active against cells derived from both solid and blood-borne cancers, including those with mutant p53. Among hematologic malignancies, we find that WINi are effective as a single agent against leukemia and diffuse large B cell lymphoma xenograft models, and can be combined with the approved drug venetoclax to suppress disseminated acute myeloid leukemia in vivo. These studies reveal actionable strategies for the application of WINi to treat blood-borne cancers and forecast expanded utility of WINi against other cancer types.<\/jats:p>","DOI":"10.1073\/pnas.2408889121","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T21:31:12Z","timestamp":1724275872000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":15,"title":["Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies"],"prefix":"10.1073","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-6522","authenticated-orcid":false,"given":"Christian T.","family":"Meyer","sequence":"first","affiliation":[{"name":"Department of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, CO 80309"},{"name":"Duet BioSystems, Nashville, TN 37212"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna N.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232"},{"name":"Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1039-015X","authenticated-orcid":false,"given":"Kevin B.","family":"Teuscher","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-8050","authenticated-orcid":false,"given":"Brian C.","family":"Grieb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8373-4573","authenticated-orcid":false,"given":"Gregory C.","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-3140","authenticated-orcid":false,"given":"Alexander J.","family":"Silver","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly L.","family":"Lorey","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-6100","authenticated-orcid":false,"given":"Gordon M.","family":"Stott","sequence":"additional","affiliation":[{"name":"Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701-4907"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-2228","authenticated-orcid":false,"given":"William J.","family":"Moore","sequence":"additional","affiliation":[{"name":"Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taekyu","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-0530","authenticated-orcid":false,"given":"April M.","family":"Weissmiller","sequence":"additional","affiliation":[{"name":"Department of Biology, Middle Tennessee State University, Murfreesboro, TN 37132"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-7078","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232"},{"name":"Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-8672","authenticated-orcid":false,"given":"Vito","family":"Quaranta","sequence":"additional","affiliation":[{"name":"Duet BioSystems, Nashville, TN 37212"},{"name":"Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-6192","authenticated-orcid":false,"given":"Stephen W.","family":"Fesik","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240"},{"name":"Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37240"},{"name":"Department of Chemistry, Vanderbilt University, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3900-0978","authenticated-orcid":false,"given":"William P.","family":"Tansey","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240"},{"name":"Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37240"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010274"},{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7020021"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.02.047"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2020.194579"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211297120"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa051"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"zcac007","DOI":"10.1093\/narcan\/zcac007","article-title":"Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells","volume":"4","author":"Florian A. C.","year":"2022","unstructured":"A. C. Florian , Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. NAR Cancer 4, zcac007 (2022), 10.1093\/narcan\/zcac007.","journal-title":"NAR Cancer"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.12.001"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05947-9"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1910391116"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90683","article-title":"Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition","volume":"12","author":"Howard G. C.","year":"2024","unstructured":"G. C. Howard , Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. Elife 12, RP90683 (2024), 10.7554\/eLife.90683.","journal-title":"Elife"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.104"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01608"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: A cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster J. M.","year":"2021","unstructured":"J. M. Dempster , Chronos: A cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 22, 343 (2021), 10.1186\/s13059-021-02540-7.","journal-title":"Genome Biol."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","article-title":"Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors","volume":"12","author":"Li W.","year":"2019","unstructured":"W. Li , Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J. Hematol. Oncol. 12, 73 (2019), 10.1186\/s13045-019-0761-2.","journal-title":"J. Hematol. Oncol."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1186-3"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"610820","DOI":"10.3389\/fonc.2020.610820","article-title":"TP53 mutations in acute myeloid leukemia: Still a daunting challenge?","volume":"10","author":"Molica M.","year":"2020","unstructured":"M. Molica, C. Mazzone, P. Niscola, P. de Fabritiis, TP53 mutations in acute myeloid leukemia: Still a daunting challenge? Front. Oncol. 10, 610820 (2020), 10.3389\/fonc.2020.610820.","journal-title":"Front. Oncol."},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3324\/haematol.2019.234872","article-title":"Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia","volume":"105","author":"van Leeuwen F. N.","year":"2020","unstructured":"F. N. van Leeuwen, Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia. Haematologica 105, 10\u201311 (2020).","journal-title":"Haematologica"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.11.013"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0150"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari R.","year":"2017","unstructured":"R. Bayat Mokhtari , Combination therapy in combating cancer. Oncotarget 8, 38022\u201338043 (2017).","journal-title":"Oncotarget"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2019.01.003"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-021-24789-z","article-title":"MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery","volume":"12","author":"Wooten D. J.","year":"2021","unstructured":"D. J. Wooten, C. T. Meyer, A. L. R. Lubbock, V. Quaranta, C. F. Lopez, MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat. Commun. 12, 4607 (2021), 10.1038\/s41467-021-24789-z.","journal-title":"Nat. Commun."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.02.023"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20378-8"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22284"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.502"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/leu.2014.281","article-title":"Hes1 suppresses acute myeloid leukemia development through FLT3 repression","volume":"29","author":"Kato T.","year":"2015","unstructured":"T. Kato , Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia 29, 576\u2013585 (2015).","journal-title":"Leukemia"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.18632\/oncotarget.27919","article-title":"Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia","volume":"12","author":"Bewersdorf J. P.","year":"2021","unstructured":"J. P. Bewersdorf, A. M. Zeidan, Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia. Oncotarget 12, 1314\u20131317 (2021).","journal-title":"Oncotarget"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5468.1053"},{"key":"e_1_3_4_34_2","first-page":"1169","article-title":"WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis","volume":"54","author":"el-Diry W. S.","year":"1994","unstructured":"W. S. el-Diry , WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169\u20131174 (1994).","journal-title":"Cancer Res."},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: Mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan R.","year":"2017","unstructured":"R. Pan , Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: Mechanisms and superior antileukemic efficacy. Cancer Cell 32, 748\u2013760.e6 (2017).","journal-title":"Cancer Cell"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-20-1346","article-title":"BET inhibition enhances the antileukemic activity of low-dose venetoclax in acute myeloid leukemia","volume":"27","author":"Ramsey H. E.","year":"2021","unstructured":"H. E. Ramsey , BET inhibition enhances the antileukemic activity of low-dose venetoclax in acute myeloid leukemia. Clin. Cancer Res. 27, 598\u2013607 (2021).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108636"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.20517\/cdr.2022.127","article-title":"Targeting MYC-driven lymphoma: Lessons learned and future directions","volume":"6","author":"Martinez-Martin S.","year":"2023","unstructured":"S. Martinez-Martin, M. E. Beaulieu, L. Soucek, Targeting MYC-driven lymphoma: Lessons learned and future directions. Cancer Drug Resist. 6, 205\u2013222 (2023).","journal-title":"Cancer Drug Resist."},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41418-024-01294-6","article-title":"The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer","volume":"31","author":"Pai C. P.","year":"2024","unstructured":"C. P. Pai , The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer. Cell Death Differ. 31, 768\u2013778 (2024), 10.1038\/s41418-024-01294-6.","journal-title":"Cell Death Differ."},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2159-8290.CD-19-0510","article-title":"Mitochondrial homeostasis in AML and gasping for response in resistance to BCL2 blockade","volume":"9","author":"Savona M. R.","year":"2019","unstructured":"M. R. Savona, J. C. Rathmell, Mitochondrial homeostasis in AML and gasping for response in resistance to BCL2 blockade. Cancer Discov. 9, 831\u2013833 (2019).","journal-title":"Cancer Discov."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier G.","year":"2020","unstructured":"G. Richard-Carpentier , Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 20, 212\u2013218 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00195"},{"key":"e_1_3_4_45_2","unstructured":"W. P. Tansey A. Foshage A. Weissmiller Q. Liu WDR5 is a conserved regulator of protein synthesis gene expression. Gene Expression Omnibus. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE136451. Deposited 27 August 2019."}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2408889121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T21:31:36Z","timestamp":1724275896000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/10.1073\/pnas.2408889121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":45,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2024,8,27]]}},"alternative-id":["10.1073\/pnas.2408889121"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2408889121","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"2024-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2408889121"}}